

Assisted reproduction technology in Australia and New Zealand 2005

Copyright of “Assisted reproduction technology in Australia and New Zealand 2005” is the property of AIHW National Perinatal Statistics Unit and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder’s express written permission. However, users may print, download, or email this report for individual use.

The Australian Institute of Health and Welfare is Australia's national health and welfare statistics and information agency. The Institute's mission is *better information and statistics for better health and wellbeing*.

The AIHW National Perinatal Statistics Unit (NPSU) is a collaborating unit of the AIHW, established in 1979. The NPSU aims to improve the health of Australian mothers and babies through the collection, analysis and reporting of information on reproductive, perinatal and maternal health. It maintains national collections on perinatal health, maternal deaths, congenital anomalies and assisted

AUSTRALIAN INSTITUTE OF HEALTH AND WELFARE
NATIONAL PERINATAL STATISTICS UNIT
AND
FERTILITY SOCIETY OF AUSTRALIA

ASSISTED REPRODUCTION TECHNOLOGY SERIES
Number 11

Assisted reproduction technology in Australia and New Zealand 2005

**Yueping Alex Wang
Jishan Dean
Elizabeth A Sullivan**

September 2007

AIHW National Perinatal Statistics Unit
Sydney

AIHW cat. no. PER 36

© Australian Institute of Health and Welfare 2007

This work is copyright. Apart from any use as permitted under the *Copyright Act 1968*, no part may be reproduced without prior written permission from the Australian Institute of Health and Welfare. Requests and enquiries concerning reproduction and rights should be directed to the Head, Business Promotion and Media Unit, Australian Institute of Health and Welfare, GPO Box 570, Canberra ACT 2601.

This publication is part of the Australian Institute of Health and Welfare's Assisted Reproduction Technology Series. A complete list of the Institute's publications is available from the Institute's website <www.aihw.gov.au>.

ISSN 1038-7234

ISBN 978 1 74024 715 3

Suggested citation

Wang YA, Dean JH and Sullivan EA 2007. Assisted reproduction technology in Australia and New Zealand 2005. Assisted reproduction technology series no. 11. Cat. No. PER 36. Sydney: AIHW National Perinatal Statistics Unit.

Australian Institute of Health and Welfare

Board Chair

Hon. Peter Collins, AM, QC

Director

Penny Allbon

Any enquiries about or comments on this publication should be directed to:

Yueping Alex Wang

Australian Institute of Health and Welfare National Perinatal Statistics Unit

Level 2, McNevin Dickson Building

Phone: (02) 9382 1014

Randwick Hospital Campus

Fax: (02) 9382 1025

Randwick NSW 2031

Email: npsu@unsw.edu.au

AUSTRALIA

Website: <www.npsu.unsw.edu.au>

Published by the Australian Institute of Health and Welfare

Printed by Union Offset Printers, Canberra

Contents

Acknowledgments.....

Acknowledgments

The Australian and New Zealand Assisted Reproduction Database (ANZARD), funded by the Fertility Society of Australia (FSA), is a collaborative effort between the Australian Institute of Health and Welfare's National Perinatal Statistics Unit (NPSU) and fertility centres in Australia and New Zealand. We recognise and thank all staff in the fertility centres for their efforts in compiling the data and providing additional information when requested.

We thank (in alphabetic order) Professor Michael Chapman, Dr Anne Clark, Dr Richard Fisher, Dr Richard Henshaw, Professor Gab Kovacs, Dr David Molloy, Dr Ossie Petrucco and Dr Adrienne Pope for peer reviewing the report. Cecilia Burke from the AIHW coordinated the printing and publication process.

The AIHW NPSU is a formally affiliated institution of the University of New South Wales (UNSW) and is linked to the School of Women's and Children's Health. We would like to acknowledge the support of the AIHW NPSU by the School of Women's and Children's Health, UNSW and the Sydney Children's Hospital.

Following is a list of the fertility centres and their directors who contributed data for this report.

Australian Capital Territory

Canberra Fertility Centre, Deakin (Dr Martyn Stafford-Bell)

Sydney IVF, Canberra (Dr Janelle McDonald)

New South Wales

Illawarra, Wollongong (Dr Chris James)
Lismore (Prof. Robert Jansen)
Liverpool (Dr Derek Lok)
Maitland (Dr Robert Woolcott)
Newcastle (Dr Robert Woolcott)
Northwest (Dr Mark Bowman)
Orange (Prof. Robert Jansen)
Port Macquarie (Dr Robert Woolcott)
Royal Prince Alfred Hospital, Camperdown (Dr Mark Bowman)
Tamworth (Prof. Robert Jansen)

Westmead Fertility Centre, Westmead (Dr Howard Smith)

Northern Territory

REPROMED Darwin, Tiwi (Dr Richard Henshaw)

Queensland

City Fertility Centre

Brisbane (Dr Glenn Sterling)

Gold Coast (Dr Glenn Sterling)

Coastal IVF, Maroochydore (Dr Paul Stokes)

IVF Bundaberg, Bundaberg (Dr James Moir)

IVF Sunshine Coast, Birtinya (Dr James Moir)

Monash IVF

Gold Coast, Southport (Dr Irving Korman)

Queensland, Sunnybank (Dr Kevin Forbes)

Rockhampton (Prof. Gab Kovacs)

The Wesley/Monash IVF Services, Auchenflower (Dr John Allan)

Townsville (Prof. Gab Kovacs)

Queensland Fertility Group

Brisbane (Dr David Molloy)

Cairns (Dr Bob Miller)

Gold Coast, Benowa (Dr Andrew Cary)

Mackay (Dr Lance Herron)

North West, Everton Park (Dr David Molloy)

Toowoomba IVF, Toowoomba (Dr John Esler)

Townsville, Hyde Park (Dr Ron Chang)

South Australia

Flinders Reproductive Medicine, Bedford Park (Dr Enzo Lombardi)

REPROMED Reproductive Medicine Unit, Dulwich (Dr Richard Henshaw)

Tasmania

Sydney IVF, Launceston (Dr Sue James)

Tasmanian IVF, Hobart (Dr Bill Watkins)

Victoria

Ballarat IVF

Bacchus Marsh (Dr Russell Dalton)

Wendouree (Dr Russell Dalton)

Melbourne Assisted Conception Centre, Heidelberg (Dr Mac Talbot)

Melbourne IVF

Freemasons Day Procedure Centre (Dr Lyndon Hale)

Reproductive Services, Royal Women's Hospital (Dr Lyndon Hale)

Monash IVF

Bairnsdale (Dr Mac Talbot)

Bendigo (Dr Nick Lolatgis)

Casterton (Prof. David Healy)

Epworth Hospital, Richmond (Dr Lynn Burmeister)

Geelong (Prof. Gab Kovacs)

Monash Surgical Private Hospital, Clayton (Dr Luk Rombauts)

Northern, Broadmeadows (Dr Luk Rombauts)

Sale (Dr Mac Talbot)

REPROMED Mildura (Dr Richard Henshaw)

Western Australia

Concept Fertility Centre, Subiaco (Dr Rob Mazzucchelli)

Fertility North, Joondalup (Dr Vince Chapple)

Hollywood IVF, Nedlands (Dr Simon Turner)

PIVET Medical Centre, Leederville (Dr John Yovich)

The Keogh Institute for Medical Research, Nedlands (Dr Bronwyn Stuckey)

Abbreviations and symbols

| | |
|--------|--|
| ACT | Australian Capital Territory |
| AI | artificial insemination |
| AIHW | Australian Institute of Health and Welfare |
| ANZARD | Australian and New Zealand Assisted Reproduction Database |
| ART | assisted reproduction technology |
| DET | double-embryo transfer |
| DI | donor sperm insemination or artificial insemination with donated sperm |
| ET | embryo transfer |
| FSH | follicle-stimulating hormone |
| g | grams |
| GIFT | gamete intrafallopian transfer |
| ICSI | intracytoplasmic sperm injection |
| IVF | in-vitro fertilisation |
| LMP | last menstrual period |
| NPSU | National Perinatal Statistics Unit |
| NSW | New South Wales |
| NT | Northern Territory |
| NZ | New Zealand |
| OHSS | ovarian hyperstimulation syndrome |
| OPU | oocyte pick-up |
| PGD | preimplantation genetic diagnosis |
| Qld | Queensland |
| RTAC | Reproductive Technology Accreditation Committee |
| SA | South Australia |
| SET | single-embryo transfer |
| Tas | Tasmania |
| UNSW | The University of New South Wales |
| Vic | Victoria |
| WA | Western Australia |
| .. | not applicable |
| | null cells |

Summary

There were 51,017 treatment cycles reported to ANZARD in Australia and New Zealand in 2005. Of these cycles, 91.1% were from Australian fertility centres and 8.9% from New Zealand's centres. There is an increase of 13.7% of ART treatment cycles from 2004.

Average age of women who had ART treatment in 2005 was 35.5 years, slightly older than average age (35.2 years) of women who had ART treatment in 2002. The proportion of women aged older than 40 years has increased from 14.3% in 2002 to 15.3% in 2005.

Since ANZARD was established in 2002 there has been a significant increase in the number of embryos transfer cycles where women received single-embryo transfers (SET). SET cycles accounted for 48.3% of embryos transfer cycles in 2005, compared to 28.4% in 2002. The increase of SET cycles resulted more singleton deliveries. The proportion of singleton deliveries was 85.9% in 2005, the highest proportion ever reported.

Babies born to women who had a single-embryo transfer had better outcomes compared to babies born to women who had a double-embryo transfer (DET). In 2005, there were 3,681 SET babies and 5,589 DET babies. In SET babies, 96.1% were singletons, compared to 61.6% singletons in DET babies. SET babies had a live birth rate of 0.0008 compared to 0.0008 in DET babies in 2005.

1 Introduction

Assisted reproduction technology in Australia and New Zealand 2005 is the 11th annual report on the use of assisted reproduction technology (ART) in Australia and New Zealand.

Fertility is defined as the ability of an individual to conceive and bear offspring. Infertility is the state of diminished or impaired capacity to do so. Infertility is not an absolute or irreversible condition but rather a clinical continuum (Carr et al. 2005). Clinicians in Australia and New Zealand have treated couples with infertility by using ART since the early 1980s.

ART treatment is available to couples in fertility centres in Australia and New Zealand. There were 30 fertility centres in Australia and 4 in New Zealand in 2005.

Aim of this report

The main objective of Australian and New Zealand Assisted Reproduction Database (ANZARD) is to assist in monitoring ART treatment and perinatal outcomes. The main aim of this report is to provide:

- information on ART treatment cycles and the resulting pregnancy outcomes in Australia and New Zealand;
- evidence of quality improvement through monitoring ART treatment practices, success rates and perinatal outcomes;
- information to inform standards for accreditation and monitoring of ART centres; and
- information for national and international comparisons.

Procedures included in this report

Assisted reproduction technology

Assisted reproduction technology encompasses procedures and techniques involving the manipulation of gametes, zygotes and embryos. The main ART procedures included in this report are:

- in-vitro fertilisation (IVF), where eggs and sperm are combined in the laboratory for fertilisation outside the body and replaced in the uterus;
- intracytoplasmic sperm injection (ICSI), where a single sperm is injected into an egg for fertilisation outside the body and replaced in the uterus; and
- gamete intrafallopian transfer (GIFT), where eggs and sperm are placed in the fallopian tubes for fertilisation inside the body.

Embryos arising from IVF and ICSI procedures can be frozen and then used in subsequent 0-9Td<0073/TI), v

Donor sperm insemination

Artificial insemination (AI) is a term that covers a range of techniques of placing sperm into the female genital tract. Such inseminations may include intravaginal insemination, intracervical insemination, intrauterine insemination, intrafallopian insemination and intraperitoneal insemination. AI is provided in medical facilities in Australia and New Zealand. It is provided in fertility centres as part of ART treatment. Information on AI using donated sperm (donor sperm insemination (DI)) performed in fertility centres in Australia and New Zealand is included in this report.

Structure of this report

This report has six chapters. Following this introduction, which briefly describes the data used in this report, Chapter 2 presents data on oocyte pick-up (OPU), IVF, ICSI, embryo transfer, the success of these ART treatments and complications of the ART treatment. Chapter 3 presents data on the outcomes, including pregnancies, deliveries and births, from embryo transfer cycles. Chapter 4 presents data on GIFT cycles (including intended GIFT cycles) and surrogacy cycles, and their subsequent outcomes in pregnancies and births. Chapter 5 presents data on DI cycles, and their subsequent outcomes in pregnancies and births. Chapter 6 presents trends in all ART treatments from 2002 to 2005 and trends in the outcomes of ART treatment from 1996 to 2005. The Appendix presents the data items in the ANZARD.

The structure of the report differs from the Assisted reproduction technology in Australia and New Zealand 2004 report. In this report, GIFT, DI and surrogacy cycles are presented in separate chapters from the ART treatment chapter. In addition, the term autologous cycle has replaced non-donor cycle. An autologous cycle is an ART treatment cycle in which patients intend to use their own oocytes/gametes.

This report and additional data on the Internet

This report is available in PDF format on the NPSU website <www.npsu.unsw.edu.au>. This website also includes supplementary tables (in PDF format) which present data not included in the report.

Data

Data source

The data presented in this report are supplied by fertility centres in Australia and New Zealand. The data are compiled into ANZARD. ANZARD includes information about the ART treatment procedures of IVF, ICSI and GIFT. It also includes information about ART treatment using thawed embryos; treatment involving donated gametes or embryos; the use of techniques such as assisted hatching, preimplantation genetic diagnosis (PGD) and blastocyst culture; and DI cycles. ANZARD also contains information on outcomes in pregnancies and births. This includes method of birth, birth status, birthweight, gestational age, plurality, perinatal mortality and selected information on maternal morbidity.

ANZARD does not contain information about artificial insemination if the woman's partner's sperm was used.

Cohort

This report presents information on all treatment cycles that took place in fertility centres in Australia and New Zealand in 2005, and their resulting pregnancies and births. The babies included in this report were conceived through the treatment cycles undertaken in 2005 and were born in either 2005 or 2006.

Data validation

Most fertility centres have computerised data management systems and are able to provide the NPSU with high-quality data. The NPSU subjects all data to an extensive process of validation. Data queries are followed up with fertility centre staff. In 2005, information relating to pregnancy and birth outcomes was not stated for less than 0.3% of cycles. The Reproductive Technology Accreditation Committee (RTAC) plays a role in ensuring the quality of ANZARD data by validating selected records against clinic files in their triennial inspections.

Data presentation

Data presented are for treatment cycles and not patients. Thus, it is possible that an individual woman can undergo more than one treatment cycle in a year or experience more than one pregnancy. This also means that information reported about patient characteristics, such as age, parity and cause of infertility, are based on calculations in which individuals

2 ART treatment in 2005

This chapter presents data on OPU, IVF, ICSI, embryo transfer, the success of ART treatment and complications of ART treatment. Since GIFT cycles (including intended GIFT cycles) and surrogacy cycles accounted for less than 0.4% of all treatment cycles, they are separately presented in Chapter 4. DI cycles are presented in Chapter 5.

2.1 ART treatment overview

ART treatment cycles


A total of 47,459 ART treatment cycles were reported to ANZARD in Australia and New Zealand in 2005 (Table 1). Of these, 91.6% (43,493) were from fertility centres in Australia and 8.4% (3,966) were in New Zealand. In Australia there were 10.1 cycles per 1,000 women of reproductive age (15–44 years) and in New Zealand there were 4.5 cycles per 1,000 women of reproductive age.

Types of ART treatment cycles

In 2005, about three-fifths (59.0%; 27,995) of cycles were autologous fresh cycles; and over a third (35.3%; 16,759) were autologous thaw cycles. Donation and recipient cycles accounted for a small portion of total treatment cycles, 3.8% (1,811) for oocytes/embryos recipient cycles and 1.9% (894) for oocyte donation cycles (Table 1 and Figure 1).

Table 1: Number of ART treatment cycles by treatment type, Australia and New Zealand, 2005

| Treatment type | Number | Per cent |
|----------------|--------|----------|
|----------------|--------|----------|



There were 894 oocyte donation fresh cycles (Table 1) and 816 oocyte recipient fresh cycles (Table 2). Of oocyte recipient fresh cycles, 38.0% (310) had an IVF procedure, 61.3% (500) had an ICSI procedure. No fertilisation was occurred in six (0.7%) oocyte recipient fresh cycles.

Thaw cycles

Thaw cycles include ART treatment cycles, with or without embryo transfers, in which cryopreserved (frozen) embryos are thawed with the intention of a transfer.

In 2005, ICSI cycles were 48.1% (8,059) and IVF cycles were 45.2% (7,578) of all autologous thaw cycles. Oocytes/embryos recipient thaw cycles had similar proportions in IVF and ICSI cycles, 47.0% and 50.1% respectively (Table 3).

Table 3: Number of thaw cycles by treatment type and procedure, Australia and New Zealand, 2005

| Procedure | Autologous | | Oocytes/embryos recipient | |
|--------------|---------------|--------------|---------------------------|--------------|
| | Number | Per cent | Number | Per cent |
| IVF | 7,578 | 45.2 | 468 | 47.0 |
| ICSI | 8,059 | 48.1 | 498 | 50.1 |
| Not stated | 1,122 | 6.7 | 29 | 2.9 |
| Total | 16,759 | 100.0 | 995 | 100.0 |

OPUs performed in 2005

OPU refers to a medical procedure that collects oocytes from ovaries by ultrasound-guided transvaginal aspiration or by laparoscopic surgery.

In 2005, there were 26,212 OPUs performed in Australia and New Zealand. The majority (96.9%) of OPUs was performed in retrieving oocytes for the patient's own use. A small proportion (3.1%; 826) of OPUs was performed for oocyte donation. Overall, more than one-third (34.4%) of OPUs was performed in women aged 38 years or older (Table 4).

Table 4: Number of OPUs by treatment type and age group, Australia and New Zealand, 2005

| Treatment type | Age groups (years) ^(a) | | | | | |
|-------------------------|-----------------------------------|-------------|--------------|-------------|---------------|--------------|
| | < 38 | | 38 | | All | |
| | Number | Per cent | Number | Per cent | Number | Per cent |
| OPU for own use | 16,463 | 64.9 | 8,923 | 35.1 | 25,386 | 100.0 |
| OPU for oocyte donation | 720 | 87.2 | 106 | 12.8 | 826 | 100.0 |
| Total | 17,183 | 65.6 | 9,029 | 34.4 | 26,212 | 100.0 |

(a) Age at time of treatment.

Number of embryos transferred per embryo transfer cycle


In 2005, about half (48.2%) of the embryo transfer cycles had a single-embryo transfer and nearly half (49.8%) of the cycles had a double-embryo transfer. The proportion of embryo transfer cycles using three or more embryos was less than 2% of all embryo transfer cycles in 2005 (Table 5). The trend of transferring a single embryo has been continuously increasing from 28.4% in 2002 to 48.2% in 2005.

Table 5: Number of embryo transfer cycles by number of embryos transferred per cycle and women's age group, Australia and New Zealand, 2005

| Number of embryos | Age group (years) ^(a) | | | | | | Total |
|-------------------|----------------------------------|--------------|---------------|---------------|--------------|--------------|---------------|
| | 24 | 25–29 | 30–34 | 35–39 | 40–44 | 45 | |
| Number | | | | | | | |
| 1 | 266 | 2,242 | 6,957 | 6,332 | 2,617 | 379 | 18,793 |
| 2 | 159 | 1,742 | 5,657 | 7,478 | 3,988 | 396 | 19,420 |
| 3 | 0 | 13 | 87 | 230 | 367 | 52 | 749 |
| Total | 425 | 3,997 | 12,701 | 14,040 | 6,972 | 827 | 38,962 |
| Per cent | | | | | | | |
| 1 | 62.6 | 56.1 | 54.8 | 45.1 | 37.5 | 45.8 | 48.2 |
| 2 | 37.4 | 43.6 | 44.5 | 53.3 | 57.2 | 47.9 | 49.8 |
| 3 | 0.0 | 0.3 | 0.7 | 1.6 | 5.3 | 6.3 | 1.9 |
| Total | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |

(a) Age at time of treatment.

The proportion of single-embryo transfer cycles decreased with advancing women's age. In general, women aged 38 years or older had more embryos transferred per cycle than those aged less than 38 years (Figures 2 and 3).






Figure 3: Proportion of thawed embryo transfer cycles by number of embryos transferred per cycle, New Zealand, 2005

Embryo development

transfer cycles had a blastocyst transfer. The proportion was originally higher in fresh cycles (23.0%) than in

embryo development, by embryo development type and stage of embryo development,

| | Thaw | All |
|-----|------|-----|
| ... | ... | ... |




Table 7: Stage/outcome of treatment cycles with preimplantation genetic diagnosis (PGD) by type of embryo, Australia and New Zealand, 2005

| Stage/outcome of treatment | Type of ART treatment | | |
|---|-----------------------|-------------|-------------|
| | Fresh | Thaw | Total |
| Number of cycles with PGD | 846 | 145 | 991 |
| Number of cycles with PGD that had embryo transferred | 586 | 120 | 706 |
| Number of cycles with PGD that resulted in a clinical pregnancy | 164 | 31 | 195 |
| Number of cycles with PGD that resulted in a live delivery | 129 | 21 | 150 |
| <i>Clinical pregnancies per PGD cycle (%)</i> | <i>19.4</i> | <i>21.4</i> | <i>19.7</i> |
| <i>Live deliveries per PGD cycle (%)</i> | <i>15.2</i> | <i>14.5</i> | <i>15.1</i> |

Women's age and their partner's age

The average age of women who underwent ART treatment in 2005 was 35.5 years, with four in five aged less than 40 years (Table 8). The partners of the women tended to be older, with an average age of 37.9 years, and just over three in five aged less than 40 years (Table 9). On average, women who used donated oocytes or embryos were older (40.5 years) than women

Cause of infertility

Causes of infertility are based on clinical diagnosis. However, the diagnostic definitions may vary among fertility centres.

In 2005, 27.0% of ART treatment cycles had male infertility factor listed as the only cause of infertility; 33.1% of cycles had female infertility factor(s) reported; 16.3% of cycles had combined male-female infertility factor(s); and 17.3% of cycles had unexplained infertility. Male infertility factor (alone and combined with female infertility factor) was reported for 43.3% of cycles.

Ovarian hyperstimulation syndrome

2.2.2 Autologous fresh cycles

Autologous fresh cycles include cycles in which OPU is performed, cycles in which thawed oocyte(s) were used in fertilisation, and cancelled cycles where follicle-stimulating hormone (FSH) was administered.

Oocyte collections

Of the 27,995 initiated autologous fresh cycles, 90.4% had an OPU and 88.9% had oocyte(s) collection. Overall, the rate of transferring embryos from autologous fresh cycles was 78.4% in 2005.

The highest rate (81.8%) was among women in 30–34 years age group in 2005. Cycles of women aged 45 years or older had the lowest rates with only 84.0% of initiated cycles had an OPU, 76.9% had oocyte(s) collected, and 59.3% had embryo(s) transferred (Table 12).

Table 12: Stage/outcome of autologous fresh cycles by women's age group, Australia and New Zealand, 2005

| Age group (years) ^(a) | Initiated cycles (number) | Cycles with OPU performed (per cent) | Cycles with oocyte collected (per cent) | Cycle with oocyte fertilised (per cent) | Cycles with embryo transferred (per cent) |
|----------------------------------|---------------------------|--------------------------------------|---|---|---|
| 24 | 321 | 85.7 | 85.4 | 81.0 | 71.7 |
| 25–29 | 2,803 | 91.8 | 91.2 | 88.1 | 79.9 |
| 30–34 | 8,536 | 92.0 | 91.5 | 88.3 | 81.8 |
| 35–39 | 10,204 | 90.5 | 89.1 | 84.5 | 79.2 |
| 40–44 | 5,694 | 87.7 | 84.4 | 77.6 | 72.8 |
| 45 | 437 | 84.0 | 76.9 | 62.9 | 59.3 |
| Total | 27,995 | 90.4 | 88.9 | 84.2 | 78.4 |

(a) Age at time of treatment.

Success in clinical pregnancies and live deliveries

The success of autologous fresh cycles can be measured in a number of ways, depending on the stage of treatment and the outcome used. Table 13 presents the various success measures that can be derived.

In 2005, the success rate for initiated cycles was 24.0% for clinical pregnancies and 19.1% for live deliveries. For embryo transfer cycles, however, the success rate was 30.6% for clinical pregnancies and 24.3% for live deliveries.

Table 13: Measure of success for autologous fresh cycles, Australia and New Zealand, 2005

| Stage of treatment | Cycles that resulted in a clinical pregnancy | Cycles that resulted in a delivery | Cycles that resulted in a live delivery |
|--------------------|--|------------------------------------|---|
| | Per cent | | |
| Initiated cycles | 24.0 (6,724/27,995) | 19.3 (5,394/27,995) | 19.1 (5,337/27,995) |
| Embryo transfers | 30.6 (6,724/21,949) | 24.6 (5,394/21,949) | 24.3 (5,337/21,949) |


Figure 4 shows:

- the total number of initiated autologous fresh cycles;
- the total number of autologous fresh cycles in which oocytes were retrieved; and
- the number of cycles in which embryos were transferred.

It also shows the number of initiated autologous fresh cycles that resulted in:

- a clinical pregnancy
- a delivery
- a live delivery.


Treatment can be discontinued for a variety of reasons, including failure of ovaries to respond to drugs, failure of oocyte fertilisation, inadequate embryo growth, development of treatment side-effects, patient choice or failure of the embryo(s) to implant in the uterus.



Success of autologous fresh cycles by women's age

Women's reproductive age is one of the key factors associated with success from ART treatment when women use their own oocytes. Figure 5 shows the success rates (measured as the proportion of initiated cycles that resulted in a live delivery) for autologous fresh cycles in 2005 by women's age. Women aged between 23 and 32 years had higher rates.

These rates then decline steadily for women older than 32 years. For women aged 45 years or more the live delivery rate was 1.6% in 2005.



Success of autologous fresh embryo transfer cycles by ART procedure

For autologous fresh embryo transfer cycles undertaken in 2005, the success rates were similar in IVF cycles and ICSI cycles. For IVF embryo transfer cycles, 31.1% resulted in a clinical pregnancy and 24.5% resulted in a live delivery. For ICSI embryo transfer cycles, 30.3% resulted in a clinical pregnancy and 24.2% resulted in a live delivery (Table 15).

Table 15: Success of autologous fresh embryo transfer cycles by stage/outcome of treatment and procedure, Australia and New Zealand, 2005

| Stage/outcome of treatment | IVF | ICSI |
|--|-------------|-------------|
| Embryo transfers | 9,145 | 12,804 |
| Clinical pregnancies | 2,841 | 3,883 |
| Live deliveries | 2,242 | 3,095 |
| <i>Clinical pregnancies per transfer cycle (%)</i> | <i>31.1</i> | <i>30.3</i> |
| <i>Live deliveries per transfer cycle (%)</i> | <i>24.5</i> | <i>24.2</i> |

Success of autologous fresh embryo transfer cycles by stage of embryo development

For autologous fresh embryo transfer cycles undertaken in 2005, the success rates were higher in blastocyst transfer cycles than in

Table 17: Number of autologous fresh cycles that resulted in a live delivery by cause of infertility, Australia and New Zealand, 2005

| Cause of infertility | Initiated cycles (number) | Cycles with embryo transfer (per cent) | Cycles that resulted in a clinical pregnancy (per cent) | Cycles that resulted in a live delivery (per cent) |
|-----------------------------|---------------------------|--|---|--|
| Male factor only | 7,880 | 82.2 | 26.1 | 21.0 |
| Female factor | | | | |
| Tubal disease only | 2,196 | 80.7 | 23.7 | 18.6 |
| Endometriosis only | 1,703 | 79.3 | 26.8 | 20.7 |
| Other female factor only | 3,768 | 71.4 | 20.2 | 16.2 |
| Combined female factor | 1,119 | 75.0 | 20.7 | 16.7 |
| Combined male/female factor | 5,003 | 78.2 | 23.6 | 18.4 |
| Unexplained | 5,157 | 78.7 | 23.6 | 18.8 |
| Not stated | 1,169 | 72.1 | 25.1 | 20.0 |
| Total | 27,995 | 78.4 | 24.0 | 19.1 |

Success of autologous fresh cycles among fertility centres

The success of autologous fresh ART treatment varied among the fertility centres in Australia and New Zealand. In 2005 among all centres, the success rates (measured as the proportion of autologous fresh cycles that resulted in a live delivery) ranged between 10.8% and 26.9% (Table 18).

Variation in success among fertility centres is best measured using quartiles which rank individual centres' success rates with the success of the top and bottom 25% of centres.

For autologous fresh cycles in 2005, the top 25% (first quartile) of fertility centres had a success rate between 20.9% and 26.9%. The bottom 25% (fourth quartile) of fertility centres had a lower success rate between 10.8% and 16.3%. The remaining 50% of fertility centres had success rates between 16.4% and 20.8% (Table 18).

Table 18: Success of autologous fresh cycles by women's age group and quartiles of success, fertility centres, Australia and New Zealand, 2005


| Age group (years) ^(a) | Live deliveries per initiated autologous fresh cycle (%) | | | | |
|----------------------------------|--|------------------|------------------|------------------|------------------|
| | Mean | First quartile | Second quartile | Third quartile | Fourth quartile |
| < 38 | 24.2 | 24.9–31.3 | 23.2–24.8 | 20.6–23.1 | 15.2–20.5 |
| 38 | 9.9 | 12.1–18.4 | 9.5–12.0 | 7.3–9.4 | 1.8–7.2 |
| All | 19.1 | 20.9–26.9 | 18.7–20.8 | 16.4–18.6 | 10.8–16.3 |

(a) Age at time of treatment.


Overall the success rate was 19.1% for autologous fresh cycles in all centres in Australia and New Zealand. Women aged less than 38 years old had a much higher success rate (24.2%) in delivering a live child following an autologous fresh cycle than those aged 38 years or older (9.9%).

Figure 6 shows the average success rate (measured as the proportion of autologous fresh cycles with embryos transferred that resulted in a live delivery) and 25th and 75th percentiles by stage of embryo development among fertility centres. Single-blastocyst transfers (unadjusted for women's age) achieved a high average rate (31.8%) in live

e(e) 107ne



between 25 and 34 years. Similar to autologous fresh cycles, the success rates declined steadily for women aged 35 years or older.



Success of autologous thaw cycles by ART procedure

For autologous thaw cycles with embryo transfers in 2005, the success rate (measured as the proportion of autologous thaw cycles with embryo transfers that resulted in a clinical pregnancy) was marginally higher for IVF cycles (21.9%) than for ICSI cycles (20.7%). The success rate (measured as the proportion of autologous thaw cycles with embryo transfers that resulted in a live delivery) was similar for IVF cycles (16.2%) and for ICSI cycles (15.8%) (Table 20).

Table 20: Success of autologous thaw cycles with

Success of autologous thaw cycles by stage of embryo development

Similar to autologous fresh cycles, the rates for clinical pregnancies and live births of autologous thaws are similar to autologous fresh cycles (ethawed)

For the top 25% (first quartile) of fertility centres, the success rates of live deliveries in autologous thaw cycles were between 17.7% and 22.6%. The bottom 25% (fourth quartile) of fertility centres had success rates between 5.6% and 11.7%. The remaining 50% of fertility centres had success rates between 11.8% and 17.6% (Table 23).

Similar to autologous fresh cycles, the success rate, on average, was much higher for women aged less than 38 years (17.1%) than for women aged 38 years or older (9.3%).

Table 23: Success of autologous thaw cycles by women's age group and quartiles of success, fertility centres, Australia and New Zealand, 2005

| Age group (years) | Live deliveries per initiated autologous thaw cycle (%) | | | | |
|-------------------|---|------------------|------------------|------------------|-----------------|
| | Mean | First quartile | Second quartile | Third quartile | Fourth quartile |
| < 38 | 17.1 | 20.6–24.7 | 16.7–20.5 | 13.7–16.6 | 5.1–13.6 |
| 38 | 9.3 | 10.1–17.9 | 8.5–10.0 | 5.4–8.4 | 0.0–5.3 |
| All | 14.9 | 17.7–22.6 | 13.8–17.6 | 11.8–13.7 | 5.6–11.7 |

2.3 Donation and recipient cycles in 2005

A donation cycle is a treatment cycle where the patients donate their oocytes, embryos or gametes to others. A recipient cycle is one in which the patients receive donated oocytes, embryos or gametes for their own ART treatment.

In 2005, donation and recipient cycles accounted for 5.7% (2,705) of all treatment cycles. Of all donation and recipient cycles, 1,710 (63.2%) cycles were fresh cycles and 995 (36.8%) were thaw cycles (Table 1).

2.3.1 Oocyte donation cycles

There were 894 initiated oocyte donation cycles reported in Australia and New Zealand in 2005, which included 68 (7.6%) cancelled cycles for oocyte donation (Figure 10). Over 90% of the initiated oocyte donation cycles resulted in donations.




Table 24: Stage/outcome of oocyte donation cycles by donor's age group, Australia and New Zealand, 2005

| Age group (years) ^(a) | Initiated cycles (number) | Cycles with OPU performed (per cent) | Cycles with oocyte collected (per cent) | Cycles with oocyte donated (per cent) |
|----------------------------------|---------------------------|--------------------------------------|---|---------------------------------------|
| 24 | 47 | 89.4 | 89.4 | 87.2 |
| 25–29 | 129 | 96.1 | 95.3 | 93.8 |
| 30–34 | 361 | 94.5 | 94.2 | 92.2 |
| 35–39 | 310 | 89.4 | 88.4 | 87.4 |
| 40 | 47 | 89.4 | 87.2 | 85.1 |
| Total | 894 | 92.4 | 91.7 | 90.2 |

(a) Age at time of treatment.


2.3.2 Oocytes/embryos recipient cycles

There were 1,811 oocytes/embryos recipient cycles reported in 2005 (Table 1). Of these recipient cycles, 88.5% (1,602) were oocyte recipient cycles and 11.5% (209) were embryo recipient cycles. The average age of women receiving donated oocytes/embryos was 40.5 years in 2005.

Success in clinical pregnancies and live deliveries

Figure 11 shows the number of recipient cycles in which embryos were transferred. It also shows the number of recipient cycles with embryo transfer that resulted in:

- a clinical pregnancy
- a delivery
-



Success of oocytes/embryos recipient cycles by ART procedure

The success rate (measured as the proportion of oocytes/embryos recipient cycles with embryo transfers that resulted in a live delivery) was higher in fresh cycles than in thaw cycles (Table 26). IVF cycles had higher success rates (27.2% in fresh cycles and 18.5% in thaw cycles) than ICSI cycles (21.9% and 11.5% respectively).

Table 26: Success of oocyte/embryo recipient cycles by treatment type and procedure, Australia and New Zealand, 2005

| Stage/outcome of treatment | Fresh | | Thaw | |
|----------------------------|-------|------|------|------|
| | IVF | ICSI | IVF | ICSI |
| Embryo transfers | 283 | 433 | 443 | 480 |
| Clinical pregnancies | 97 | 139 | 100 | 85 |
| Live deliveries | 77 | 95 | 82 | 55 |

3 Pregnancies, deliveries and births following embryo transfer cycles in 2005

3.1 Clinical pregnancies and deliveries following embryo transfer cycles in 2005

Clinical pregnancies overview

There were 10,450 embryo transfer cycles that resulted in a clinical pregnancy in 2005 in Australia and New Zealand. Of these cycles, 9,403 (89.9%) were in fertility centres in Australia, and 1,047 (10.1%) were in New Zealand.

In 2005, less than one in five (2,094 out of 10,450) of clinical pregnancies did not reach 20 weeks gestation. More than three-quarters (78.6%; 8,215) of clinical pregnancies had a delivery. There were 141 (1.4%) clinical pregnancies without information on gestational age and birthweight as it was lost in follow-up or contact by the fertility centres.

Early pregnancy loss

There were 2,094 early pregnancy losses reported following embryo transfers in 2005. Of these early pregnancy losses, 90.1% were miscarriages, 7.0% were ectopic or heterotopic pregnancies and 2.9% were due to fetal reduction or termination of pregnancy (Table 28).

Oocytes/embryos recipients had the highest proportion (95.4%) of miscarriages and the lowest proportion (3.7%) of ectopic or heterotopic pregnancies in early pregnancy losses. Compared to recipients, the women in autologous cycles had higher proportions (7.0%) of ectopic or heterotopic pregnancies.

Table 28: Number of embryo transfer cycles that resulted in a clinical pregnancy of < 20 weeks gestation by pregnancy outcome, treatment type and procedure, Australia and New Zealand, 2005

Deliveries

There were 8,215 women who gave birth following embryo transfers in 2005. Of these women, 99.0% had delivered at least one liveborn baby. Fetal deaths were 0.9% of all deliveries in 2005 (Table 29).

The proportion of live deliveries amongst all deliveries following autologous fresh cycles (98.9%) was slightly lower than the proportion of live deliveries following autologous thaw cycles (99.2%). For oocyte recipient cycles that resulted in a delivery, 99.6% were live deliveries. For embryo recipient cycles that resulted in a delivery, 97.0% were live deliveries.

Table 29: Number of embryo transfer cycles that resulted in a delivery by delivery outcome, treatment type and procedure, Australia and New Zealand, 2005

| Delivery outcome | Autologous | | | Oocytes/embryos recipient | All |
|----------------------------|-----------------|--------------|--------------|---------------------------|--------------|
| | Fresh IVF | Fresh ICSI | Thaw | | |
| | Number | | | | |
| Live delivery | 2,242 | 3,095 | 2,489 | 309 | 8,135 |
| Fetal death ^(a) | 22 | 31 | 16 | 2 | 71 |
| Not stated | 2 | 2 | 5 | 0 | 9 |
| Total | 2,266 | 3,128 | 2,510 | 311 | 8,215 |
| | Per cent | | | | |
| Live delivery | 98.9 | 98.9 | 99.2 | 99.4 | 99.0 |
| Fetal death ^(a) | 1.0 | 1.0 | 0.6 | 0.6 | 0.9 |
| Not stated | 0.1 | 0.1 | 0.2 | 0.0 | 0.1 |
| Total | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |

(a) Fetal death is reported by patients to fertility centre staff. These data are not official vital statistics.

Proportion of multiple gestation pregnancies by the number of embryos transferred

In 2005, double-embryo transfer cycles accounted for 54.7% of clinical pregnancies. Single-embryo transfer cycles contributed 43.9% of all clinical pregnancies. This proportion of single-embryo transfer cycles is higher than that in 2004 (34.6%) (Wang et al. 2006). A small proportion (1.4%) of clinical pregnancies was a result of a transfer of more than two embryos (Table 30).

Multiple gestation pregnancies are closely related to the number of embryos transferred in ART treatment. In double-embryo transfer cycles, two fetal hearts were detected in 21.3% of

Table 30: Number of embryo transfer cycles that resulted in a clinical pregnancy by number of fetal hearts and number of embryos transferred, Australia and New Zealand, 2005

| Number of fetal hearts | One | | Two | | Three or more | | Total | |
|------------------------|--------------|--------------|--------------|--------------|---------------|--------------|---------------|--------------|
| | Number | Per cent | Number | Per cent | Number | Per cent | Number | Per cent |
| 0 ^(a) | 420 | 9.2 | 393 | 6.9 | 18 | 11.9 | 831 | 8.0 |
| 1 | 3,953 | 86.3 | 3,789 | 66.3 | 91 | 60.3 | 7,833 | 75.0 |
| 2 | 87 | 1.9 | 1,217 | 21.3 | 22 | 14.6 | 1,326 | 12.7 |
| 3 | 3 | 0.1 | 26 | 0.5 | 6 | 4.0 | 35 | 0.3 |
| Not stated | 119 | 2.6 | 292 | 5.1 | 14 | 9.3 | 425 | 4.1 |
| Total | 4,582 | 100.0 | 5,717 | 100.0 | 151 | 100.0 | 10,450 | 100.0 |

(a) No fetal heart detected at the time of ultrasound.

Note: A clinical pregnancy that fulfils one of the following criteria: 1. Known to be ongoing at 20 weeks; 2. Evidence by ultrasound of an intrauterine sac (with or without a fetal heart); 3. Examination of products of conception reveal chorionic villi; or 4. An ectopic pregnancy has been diagnosed by laparoscope or by ultrasound.

Multiple gestation deliveries by the number of embryos transferred

In 2005, there were 8,215 deliveries from 10,450 clinical pregnancies following ART treatment. Of these deliveries, 14.0% (1,154) were twin or triplet deliveries (Table 31). This proportion of multiple deliveries is lower than that in 2004 (16.3%) (Wang et al. 2006).

There were 1,128 twin deliveries in 2005, accounting for 13.7% of all deliveries. The proportion of twin deliveries is lower than the 16.0% of twin deliveries in 2004 (Wang et al. 2006). The majority of twin deliveries were from double-embryo transfer cycles (92.5%; 1,043). In double-embryo transfer cycles that resulted in a delivery, the proportion of twin deliveries was 23.1%. Single-embryo transfer cycles that resulted in a delivery had 1.9% of twin deliveries.

There were a small number (26 out of 8,215) of triplet deliveries in 2005.

Table 31: Number of embryo transfer cycles that resulted in a delivery by gestation and number of embryos transferred, Australia and New Zealand, 2005

| Gestation | One | | Two | | Three or more | | Total | |
|--------------|--------------|--------------|--------------|--------------|---------------|--------------|--------------|--------------|
| | Number | Per cent | Number | Per cent | Number | Per cent | Number | Per cent |
| Singleton | 3,539 | 98.1 | 3,446 | 76.4 | 76 | 77.6 | 7,061 | 86.0 |
| Twin | 68 | 1.9 | 1,043 | 23.1 | 17 | 17.3 | 1,128 | 13.7 |
| Triplet | 2 | 0.1 | 19 | 0.4 | 5 | 5.1 | 26 | 0.3 |
| Total | 3,609 | 100.0 | 4,508 | 100.0 | 98 | 100.0 | 8,215 | 100.0 |

Multiple gestation delivery by maternal age

The average age (at delivery) of women who had a delivery following embryo transfers in 2005 was 34.7 years, slightly older than the average age (34.5 years) of women who had a delivery following embryo transfers in 2004 (Wang et al. 2006). The average age of women who had a delivery following embryo transfers in 2005 is 5.0 years older than the average age (29.7 years) of all women who gave birth in Australia in 2004 (Laws et al. 2006).

Women aged less than 38 years had a higher pr(years h(0)4((.-1(91 Tw 20.623 0 Tdöporation ofmMulti)-5pl

The rate of caesarean section deliveries increases with advancing women's age at delivery. For women aged less than 38 years who had embryo transfers in 2005, 46.9% had a caesarean section. For women aged 38 years or older, the rate was 59.2%. The lowest rate of caesarean section deliveries was 29.9% in women aged less than 24 years in 2005 (Table 34).

Table 34: Number of embryo transfer cycles that resulted in a delivery by method of delivery and maternal age group, Australia and New Zealand, 2005

| Method of delivery | Age group (years) ^(a) | | | | | | Total ^(b) | < 38 | 38 |
|--------------------|----------------------------------|-------|-------|-------|-------|----|----------------------|------|----|
| | 24 | 25–29 | 30–34 | 35–39 | 40–44 | 45 | | | |
| | Number | | | | | | | | |

(Laws et al. 2006). The high proportion of babies born preterm is likely to be related to the higher proportion of multiple births among babies born to women who had ART treatment.

The average gestational age of singletons born to women who had embryo transfers in 2005 was 38.4 weeks, for twins it was 34.9 weeks and 31.0 weeks for triplets. One in ten singletons was born preterm. Multiples had much higher proportions of preterm babies. In twins it was 61.3% and 96.2% for triplets (Table 35).

Table 35: Number of babies born to women who had embryo transfer cycles by gestational age and plurality, Australia and New Zealand, 2005

| Gestational age (weeks) | Singleton | | Twin | | Triplet | | Total | |
|-------------------------|-----------|----------|--------|----------|---------|----------|--------|----------|
| | Number | Per cent | Number | Per cent | Number | Per cent | Number | Per cent |
| <i>Mean (weeks)</i> | | 38.4 | | 34.9 | | 31.0 | | 37.5 |

Figure 12 shows the distribution of gestational age for babies born to women who had embryo transfers in 2005. Most were full-term (76.7%). This is slightly higher than the proportion (74.7%) of full-term babies born to women who had ART treatment in 2004 (Wang et al. 2006). Of babies born to women who had embryo transfers in 2005, 18.5% were born at 32–36 weeks and a further 4.8% were born at less than 32 weeks (Table 35).




Figure 13 shows the dist

Sex distribution in liveborn babies

For liveborn babies to women who had embryo transfers in 2005, there were 105.1 male babies for every 100 female babies. For liveborn babies to women who had autologous fresh IVF embryo transfers in 2005, the ratio was 113.9. For liveborn babies to women who had autologous fresh ICSI embryo transfers, the ratio was 97.7 (Table 37).

Table 37: Number of liveborn babies to women who had embryo transfer cycles by sex, treatment type and procedure, Australia and New Zealand, 2005

| Sex | Autologous | | | Oocytes/embryos recipient | All |
|----------------------------|-----------------|--------------|--------------|---------------------------|--------------|
| | Fresh IVF | Fresh ICSI | Thaw | | |
| | Number | | | | |
| Male | 1,385 | 1,749 | 1,420 | 191 | 4,745 |
| Female | 1,216 | 1,791 | 1,337 | 171 | 4,515 |
| Not stated | 4 | 11 | 7 | 1 | 23 |
| Total | 2,605 | 3,551 | 2,764 | 363 | 9,283 |
| | Per cent | | | | |
| Male | 53.2 | 49.3 | 51.4 | 52.6 | 51.1 |
| Female | 46.7 | 50.4 | 48.4 | 47.1 | 48.6 |
| <i>Ratio^(a)</i> | <i>113.9</i> | <i>97.7</i> | <i>106.2</i> | <i>111.7</i> | <i>105.1</i> |

(a) Number of males to 100 females.

Perinatal mortality in all babies

Perinatal mortality is a measure for fetal deaths (stillbirths) and the deaths of liveborn babies occurring within 28 days of birth (neonatal deaths). There were 138 perinatal deaths in 2005. Of these, 102 were fetal deaths and 36 were neonatal deaths. The perinatal death rate in 2005 was 14.7 deaths per 1,000 births (Table 38). It is lower than the rate of 19.3 deaths per 1,000 births to women who had ART treatment in 2004 (Wang et al. 2006). However, this rate is higher than the rate of 10.2 deaths per 1,000 births women who gave birth in Australia in 2004 (Laws et al. 2006).

Table 38: Perinatal mortality of babies born to women who had embryo transfer cycles by type of death and plurality, Australia and New Zealand, 2005

| Type of death | Singleton | Twin | Triplet | Total |
|--|------------------------------|-------------|--------------|-------------|
| | Number | | | |
| Fetal deaths | 56 | 41 | 5 | 102 |
| Neonatal deaths | 12 | 20 | 4 | 36 |
| Perinatal deaths^(a) | 68 | 61 | 9 | 138 |
| | Rate per 1,000 births | | | |
| <i>Fetal deaths per 1,000 births</i> | <i>7.9</i> | <i>18.2</i> | <i>64.1</i> | <i>10.9</i> |
| <i>Neonatal deaths per 1,000 live births</i> | <i>1.7</i> | <i>9.0</i> | <i>54.8</i> | <i>3.9</i> |
| <i>Perinatal deaths per 1,000 births^(b)</i> | <i>9.6</i> | <i>27.0</i> | <i>115.4</i> | <i>14.7</i> |

(a) Perinatal deaths are reported by patients to fertility centre staff. These data are not official vital statistics.

(b) Fetal and perinatal death rates were calculated using all births (live births and fetal deaths) to women who had ART treatment in 2005. Neonatal death rates were calculated using all live births to women who had embryos transfer cycles in 2005.

Singletons had the lowest perinatal mortality rate of 9.6 deaths per 1,000 births and twins had a higher rate of 27.0 deaths per 1,000 births (Table 38).

In 2005, information relating to pregnancy and birth outcomes was not stated for less than 0.3% of cycles. Even for cycles in which there is successful follow-up, data are limited by the self-reported nature of the information, especially on pregnancy complications and infant morbidity. Data on perinatal mortality should be interpreted with caution because of the small numbers and potential variability in case reporting.

3.2.2 Baby outcomes single-embryo transfers and double-embryo transfers

There were 3,681 babies born to women who had a single-embryo transfer (SET) in 2005, and 5,589 babies born to women who had a double-embryo transfer (DET). The majority (96.1%) of SET babies were singletons. Less than three in five (61.7%) DET babies were singletons (Tables 39 and 40).

Perinatal outcomes of babies born following SET and DET

The adverse perinatal outcomes of babies born to women who had ART treatment can be measured in the proportions of preterm babies (born before 37 weeks gestation), babies born in low birthweight (less than 2,500 grams) and perinatal deaths. Table 39 presents the perinatal outcomes of babies born to women who had single-embryo transfers in 2005. Table 40 presents the perinatal outcomes of babies from double-embryo transfers.

The proportion of preterm babies was 11.7% for SET babies and 30.6% for DET babies.

Similarly, only 8.0% of SET liveborn babies were low birthweight, compared to 25.0% of DET

Table 39: Perinatal outcomes of babies born to women who had single embryo transfer cycles by

Table 40: Perinatal outcomes of babies born to women who had double embryo transfer cycles by plurality, Australia and New Zealand, 2005

| Perinatal outcome | Singleton | | Multiple | | Total | |
|---|--------------|--------------|--------------|--------------|--------------|--------------|
| | Number | Per cent | Number | Per cent | Number | Per cent |
| Gestational age (weeks) | | | | | | |
| 37 | 3,066 | 89.0 | 806 | 37.6 | 3,872 | 69.3 |
| 20–36 | 380 | 11.0 | 1,333 | 62.2 | 1,713 | 30.6 |
| Not stated | 0 | 0.0 | 4 | 0.2 | 4 | 0.1 |
| Total | 3,446 | 100.0 | 2,143 | 100.0 | 5,589 | 100.0 |
| Birthweight of liveborn babies (grams) | | | | | | |
| 2500 | 3,107 | 91.3 | 988 | 47.1 | 4,095 | 74.4 |
| < 2500 | 269 | 7.9 | 1,104 | 52.6 | 1,373 | 25.0 |
| Not stated | 28 | 0.8 | 7 | 0.3 | 35 | 0.6 |
| Total | 3,404 | 100.0 | 2,099 | 100.0 | 5,503 | 100.0 |
| Baby outcome | | | | | | |
| Live birth—survived | 3,398 | 98.6 | 2,079 | 97.0 | 5,477 | 98.0 |
| Live birth—neonatal death | 6 | 0.2 | 20 | 0.9 | 26 | 0.5 |
| Fetal death | 36 | 1.0 | 42 | 2.0 | 78 | 1.4 |
| Not stated | 6 | 0.2 | 2 | 0.1 | 8 | 0.1 |
| Total | 3,446 | 100.0 | 2,143 | 100.0 | 5,589 | 100.0 |
| <i>Perinatal deaths per 1,000 births^{(a)(b)}</i> | 12.2 | | 28.9 | | 18.6 | |

(a) Perinatal deaths are reported by patients to fertility centre staff. These data are no

4 GIFT and surrogacy cycles in 2005

4.1 GIFT cycles

The use of gamete intrafallopian transfer (GIFT) procedure as part of ART treatment provided in Australia and New Zealand is in decline in recent years. In 2005, there were 138 GIFT cycles reported to ANZARD. Of these GIFT cycles, 123 (89.1%) had oocytes transferred. One in four (25.4%; 35) GIFT cycles resulted in a clinical pregnancy. Less than one in five (18.1%; 25) women had a live delivery after GIFT treatment in 2005. Multiple gestation deliveries accounted for 28.0% (7 of 25) of all deliveries.

All 33 babies born to women who had GIFT treatment in 2005 were liveborn. Of these, 36.4% (12) were born preterm and 36.4% (12) were low birthweight.

4.2 Surrogacy cycles

There were 64 surrogacy cycles reported to ANZARD in 2005. Thirty-nine were surrogacy carrier cycles. Among surrogacy carrier cycles, seven (17.9%) resulted in a clinical pregnancy and six (15.4%) resulted in a live delivery. All six babies born to surrogacy carriers in 2005 were liveborn.

5 Donor sperm insemination (DI) cycles in 2005

5.1 DI cycles performed in 2005

The information presented here does not include DI cycles undertaken in hospitals or private clinics that are not fertility centres. Only DI cycles undertaken in fertility centres in Australia and New Zealand are included in this section.

The success of DI cycles is measured as the propor

6 Trends in ART treatment and outcomes of ART treatment

This chapter includes autologous cycles, donation and recipient cycles, GIFT cycles,

Table 43: Number of ART treatment cycles with oocytes/embryos transfer by treatment type and procedure, Australia and New Zealand, 2002 to 2005

| Treatment type/procedure | 2002 | | 2003 | | 2004 | | 2005 | |
|--------------------------|---------------|--------------|---------------|--------------|---------------|--------------|---------------|--------------|
| | Number | Per cent | Number | Per cent | Number | Per cent | Number | Per cent |
| Fresh | | | | | | | | |
| IVF | 6,874 | 24.5 | 7,362 | 24.4 | 8,383 | 24.5 | 9,414 | 24.1 |
| ICSI | 9,354 | 33.4 | 10,069 | 33.4 | 11,560 | 33.8 | 13,251 | 33.9 |
| GIFT | 190 | 0.7 | 183 | 0.6 | 138 | 0.4 | 123 | 0.3 |
| Thaw | | | | | | | | |
| IVF | 5,150 | 18.4 | 5,586 | 18.5 | 6,447 | 18.8 | 7,545 | 19.3 |
| ICSI | 6,153 | 21.9 | 6,449 | 21.4 | 7,181 | 21.0 | 8,169 | 20.9 |
| Not stated | 274 | 1.0 | 523 | 1.7 | 517 | 1.5 | 618 | 1.6 |
| Unclassified | 41 | 0.1 | 12 | 0.0 | 6 | 0.0 | 1 | 0.0 |
| Total | 28,036 | 100.0 | 30,184 | 100.0 | 34,232 | 100.0 | 39,121 | 100.0 |

Women's age

Women who had ART treatment in 2005 were on average slightly older (35.5 years) than women who had treatment in 2002 (35.2 years). The majority of women who had treatment were aged between 30 and 40 years old. The proportions of these women were 71.6% in 2002, 71.5% in 2003, 72.1% in 2004 and 72.3% in 2005. The proportion of women aged older than 40 years has increased from 14.3% in 2002 to 15.3% in 2005 (Table 44).


Table 44: Number of ART treatment cycles by women's age group, Australia and New Zealand, 2002 to 2005

| Age group (years) ^(a) | 2002 | | 2003 | | 2004 | | 2005 | |
|----------------------------------|--------|----------|--------|----------|--------|----------|--------|----------|
| | Number | Per cent | Number | Per cent | Number | Per cent | Number | Per cent |
| <i>Mean (years)</i> | 35.2 | | 35.2 | | 35.4 | | 35.5 | |
| 24 | 412 | 1.2 | 474 | 1.3 | 504 | 1.2 | 544 | 1.1 |
| 25–29 | 3,790 | 11.1 | 4,085 | 11.1 | 4,298 | 10.3 | 4,724 | 9.9 |
| 30–34 | 10,937 | 31.9 | 11,914 | 32.2 | 13,340 | 31.8 | 14,868 | 31.2 |
| 35–37 | 7,102 | 20.7 | 7,746 | 21.0 | 9,090 | 21.7 | 10,589 | 22.2 |
| 38–40 | 6,516 | 19.0 | 6,775 | 18.3 | 7,776 | 18.6 | 9,007 | 18.9 |
| 41–42 | 2,727 | 8.0 | 3,134 | 8.5 | 3,476 | 8.3 | 3,941 | 8.3 |
| 43–44 | 1,389 | 4.1 | 1,480 | 4.0 | 1,886 | 4.5 | 2,249 | 4.7 |
| 45 | 754 | 2.2 | 789 | 2.1 | 999 | 2.4 | 1,084 | 2.3 |
| Other/not stated | 640 | 1.9 | 569 | 1.5 | 535 | 1.3 | 655 | 1.4 |

6.2 Trends in the outcomes of ART treatment 1996 to 2005

Clinical pregnancies and live deliveries

Between 1996 and 2005, there was a steady increase in the numbers of clinical pregnancies and live deliveries resulting from ART treatment in Australia and New Zealand (Figure 15). This increase is a result of the increase in the number of ART treatment cycles provided by fertility centres in Australia and New Zealand. In 2005, there were 8,166 live deliveries, 2.8 times the 2,765 live deliveries in 1996. This significant increase represents a growth of 725 clinical pregnancies per year and 575 live deliveries per year ($p < 0.01$) between 1996 and 2005 in Australia and New Zealand.



Multiple gestation deliveries

Between 1996 and 2005, there was a decrease in the number of triplet or higher order multiple gestation deliveries that resulted from ART treatment. In 1996, 1.9% of deliveries were triplet or higher order multiple, compared with 0.3% in 2005 (Table 46). Of all deliveries, the proportion of twin deliveries significantly declined to 13.8% in 2005. It is also the lowest proportion in twin deliveries since ANZARD was established in 2002 ($p < 0.01$).

Table 46: Number of ART treatment cycles that resulted in a delivery by plurality, Australia and New Zealand, 1996 to 2005

| Year | Singleton | | Twin | | Higher order multiple | | Total |
|------|-----------|----------|--------|----------|-----------------------|----------|----------------------|
| | Number | Per cent | Number | Per cent | Number | Per cent | |
| 1996 | 2,250 | 80.1 | 508 | 18.1 | 52 | 1.9 | 2,810 |
| 1997 | 2,480 | 79.4 | 591 | 18.9 | 51 | 1.6 | 3,122 |
| 1998 | 2,748 | 79.9 | 645 | 18.8 | 47 | 1.4 | 3,440 |
| 1999 | 3,014 | 78.2 | 789 | 20.5 | 50 | 1.3 | 3,853 |
| 2000 | 3,335 | 78.0 | 901 | 21.1 | 42 | 1.0 | 4,278 |
| 2001 | 4,087 | 78.3 | 1,097 | 21.0 | 35 | 0.7 | 5,219 |
| 2002 | 4,536 | 80.0 | 1,068 | 18.8 | 33 | 0.6 | 5,671 ^(a) |
| 2003 | 4,951 | 80.9 | 1,124 | 18.4 | 21 | 0.3 | 6,123 ^(a) |
| 2004 | 5,740 | 82.8 | 1,114 | 16.1 | 23 | 0.3 | 6,932 ^(a) |
| 2005 | 7,085 | 85.9 | 1,134 | 13.8 | 27 | 0.3 | 8,246 |

(a) Includes cycles in which plurality was unknown.

Note: 1996–2001 data are from the Assisted Conception Data Collection.

Appendix: ANZARD data items

| Variable | Data domain |
|---------------------------------------|--|
| Unit identifier | 3-digit code for clinics provided by NPSU |
| Site of main treatment | For centres with multiple sites, this identifies location of most significant part of the treatment. |
| Unit patient ID/Medical record number | Unique ID for patient. |
| Woman's date of birth | Day/month/year. |
| Husband/male partner DOB | Day/month/year. |

| Variable | Data domain |
|--|---|
| Number of eggs GIFT | Number of eggs replaced in a GIFT procedure. |
| Number of eggs IVF | Number of eggs treated with IVF. |
| Number of eggs ICSI | Number of eggs treated with ICSI. |
| Site of sperm used | Site of sperm extraction: ejaculated, epididymal (whether by open biopsy or by PESA), testicular or other. |
| Person from which sperm derives | Husband/partner (h), known donor (k), Anonymous Donor (a), Embryo received or embryo transferred is a donated embryo (e) |
| Number of eggs fertilised normally | Number of eggs fertilised normally. |
| Preimplantation genetic diagnosis | Yes—preimplantation genetic diagnosis in any form (including aneuploidy screening or sex selection) has been performed on any of the embryos (transferred or not). No—PGD not performed. |
| Assisted hatching | Yes—where assisted hatching in any form has been performed on any of the embryos (transferred or not). No—assisted hatching not performed. |
| Number of embryos received from someone else or imported into the unit | To minimise the number of required fields in the data collection, this field serves two purposes: 1. Records the number of embryos to be received from donation (recipient cycle); or 2. Records the number of embryos to be imported into the current unit from another unit. |
| Number of cleavage embryos thawed | Number of zygotes or cleavage stage embryos (up to 4 days) thawed with intention of performing an embryo transfer if they survive. |
| Number of blastocysts thawed | Number of blastocysts (i.e. greater than 4 days culture from fertilisation) thawed with intention of performing an embryo transfer if they survive. |
| ET date | Embryo transfer date. |
| Number of early embryos transferred | Number of zygote or cleavage stage embryos (i.e. up to 4 days since fertilisation) transferred. |
| Number of blastocysts transferred | Number of blastocyst embryos (i.e. > 4 days since fertilisation) transferred. |
| Any embryos ICSI? | Yes—any embryos transferred were fertilised by ICSI. No—no transferred embryos were fertilised by ICSI. |
| Number of zygotes/cleavage stage embryos frozen | Number of zygote or cleavage stage embryos (i.e. up to 4 days since fertilisation) frozen. |
| Number of blastocysts frozen | Number of blastocyst embryos (i.e. > 4 days since fertilisation) frozen. |
| Number of embryos donated to someone else or exported from the unit of treatment | To minimise the number of required fields in the data collection, this field serves two purposes: 1. Records the number of embryos to be donated to someone else (donor cycle); or 2. Records the number of embryos to be exported from the current unit to another unit. |
| Number of potentially usable frozen embryos discarded | Potentially usable embryos disposed of in accordance with patient or government request. |
| Clinical pregnancy | A pregnancy that fulfils one of the following criteria: 1. Known to be ongoing at 20 weeks; 2. Evidence by ultrasound of an intrauterine sac (with or without a fetal heart); 3. Examination of products of conception reveal chorionic villi; or 4. A definite ectopic pregnancy that has been diagnosed laparoscopically or by ultrasound. |
| Date pregnancy ended | Date on which delivery, miscarriage or termination takes place. |
| Number of fetal hearts | Number of fetal hearts seen on first ultrasound (intrauterine only). |
| Ectopic pregnancy | Yes—pregnancy is an ectopic pregnancy, or a combined ectopic and uterine (heterotopic) pregnancy. No—pregnancy not ectopic or heterotopic. |
| Elective termination of pregnancy | Yes—pregnancy is terminated. No—pregnancy not terminated. |
| Selective reduction performed | Yes—selective reduction was performed owing to fetal abnormality. No—selective reduction not performed. |

| Variable | Data domain |
|---|--|
| Fetal abnormality in a pregnancy ending < 20 weeks or in a fetus removed by selective reduction | Details of elective terminations of pregnancy and fetal reductions due to fetal abnormality. |
| Maternal complications of pregnancy | Describes morbidity related to pregnancy. |
| Number of babies delivered | Include all liveborn and stillborn babies. |
| Caesarean delivery | Yes—delivery by planned or emergency caesarean section. No—other. |
| Baby 1 outcome | Liveborn, stillborn or neonatal death. |
| Baby 1 sex | Male or female. |
| Baby 1 birthweight | Weight in grams. |
| Baby 1 abnormality | Describes any known congenital malformation. |

Terminology used in this report

This report categorises ART treatments according to whether the patient used her own oocytes or embryos, or oocytes/embryos donated by another woman/couple, and whether the embryos were transferred soon after fertilisation or following cryopreservation.

Autologous cycle: an ART treatment cycle in which patients intend to use their own oocytes/gametes.

Cancelled cycle: a cycle which is started and no further procedures undertaken.

Clinical pregnancy: a pregnancy in which at least one of the following criteria is met:

- known to be ongoing at 20 weeks;
- evidence by ultrasound of an intrauterine sac (with or without a fetal heart);
- examination of products of conception reveal chorionic villi; or
- an ectopic pregnancy has been diagnosed by laparoscope or by ultrasound.

Delivery: a birth event in which one or more babies of 20 weeks or more of gestation or of 400 grams or more in birthweight are born.

DI cycle: an artificial insemination cycle in which donated sperm is used in the procedure.

Donation cycle: an ART treatment cycle in which a woman intends to donate or donates her oocytes/embryos.

ET: an embryo transfer cycle in which embryo(s) are placed in the uterus or fallopian tube. The embryo(s) can be fresh or thawed following cryopreservation. Embryo transfer includes transfer of cleavage stage embryos (two to three days after fertilisation) or transfer of blastocysts (five to six days after fertilisation).

Fresh cycle: an ART treatment cycle in which oocyte pick-up (OPU) is performed. It also includes cancelled OPU cycles, failed OPU cycles and cycles where thawed oocytes were used in fertilisation.

Full-term: a gestation of at least 37 weeks.

Gestational age: the completed weeks of gestation of the fetus at the time of delivery. This is calculated as follows:

- Fresh and thaw cycles with embryo transfer (cleavage):
(pregnancy end date – embryo transfer date) + 16 days
- Fresh and thaw cycles with embryo transfer (blastocyst):
(pregnancy end date – embryo transfer date) + 19 days

In this report, for cycles with blastocyst transfer, gestational age was estimated using the calculation that is used for cycles with cleavage transfer.

- GIFT cycles:
(pregnancy end date – OPU date) + 14 days

- DI cycles:
(pregnancy end date – date of insemination) + 14 days

GIFT cycle: an ART treatment cycle in which a GIFT procedure is used. Cycles using both GIFT and IVF/ICSI procedures are included.

ICSI cycle: an ART treatment cycle in which embryos

List of tables

| | | |
|-----------|--|----|
| Table 1: | Number of ART treatment cycles by treatment type, Australia and New Zealand, 2005..... | 4 |
| Table 2: | Number of fresh cycles by treatment type and procedure, Australia and New Zealand, 2005..... | 5 |
| Table 3: | Number of thaw cycles by treatment type and procedure, Australia and New Zealand, 2005..... | 6 |
| Table 4: | Number of OPUs by treatment type and age group, Australia and New Zealand, 2005..... | 6 |
| Table 5: | Number of embryo transfer cycles by number of embryos transferred per cycle and women's age group, Australia and New Zealand, 2005..... | 7 |
| Table 6: | Number of embryo transfer cycles by treatment type and stage of embryo development, Australia and New Zealand, 2005..... | 8 |
| Table 7: | Stage/outcome of treatment cycles with preimplantation genetic diagnosis (PGD) by type of embryo, Australia and New Zealand, 2005..... | 9 |
| Table 8: | Number of ART treatment cycles by women's age group, treatment type and procedure, Australia and New Zealand, 2005..... | 9 |
| Table 9: | Number of ART treatment cycles by women's partner's age group, treatment type and procedure, Australia and New Zealand, 2005..... | 10 |
| Table 10: | Number of ART treatment cycles with single embryo transfer by treatment type and women's age group, Australia and New Zealand, 2005..... | 10 |
| Table 11: | Number of OPUs with ovarian hyperstimulation syndrome (OHSS) by number of oocytes collected, Australia and New Zealand, 2005..... | 11 |
| Table 12: | Stage/outcome of autologous fresh cycles by women's age group, Australia and New Zealand, 2005..... | 12 |
| Table 13: | Measure of success for autologous fresh cycles, Australia and New Zealand, 2005..... | 12 |
| Table 14: | Success of autologous fresh cycles by stage/outcome of treatment and women's age group, Australia and New Zealand, 2005..... | 14 |
| Table 15: | Success of autologous fresh embryo transfer cycles by stage/outcome of treatment and procedure, Australia and New Zealand, 2005..... | 15 |
| Table 16: | Success of autologous fresh embryo transfer cycles by stage/outcome of treatment and stage of embryo development, Australia and New Zealand, 2005..... | 15 |
| Table 17: | Number of autologous fresh cycles that resulted in a live delivery by cause of infertility, Australia and New Zealand, 2005..... | 16 |
| Table 18: | Success of autologous fresh cycles by women's age group and quartiles of success, | |

| | |
|--|----|
| Table 23: Success of autologous thaw cycles by women's age group and quartiles of success, fertility centres, Australia and New Zealand, 2005 | 21 |
| Table 24: Stage/outcome of oocyte donation cycles by donor's age group, Australia and New Zealand, 2005 | 23 |
| Table 25: Success of oocytes/embryos recipient cycles by stage/outcome of treatment and recipient's age group, Australia and New Zealand, 2005 | 24 |
| Table 26: Success of oocyte/embryo recipient cycles by treatment type and procedure, Australia and New Zealand, 2005 | 25 |
| Table 27: Success of oocytes/embryos recipient cycles by treatment type and stage of embryo, Australia and New Zealand, 2005 | 25 |
| Table 28: Number of embryo transfer cycles that resulted in a clinical pregnancy of < 20 weeks gestation | |

| | |
|--|----|
| Table 45: Number of ART treatment cycles with embryo transfer by stage/outcome of treatment, treatment type and number of embryos transferred, Australia and New Zealand, 2002 to 2005 | 44 |
| Table 46: Number of ART treatment cycles that resulted in a delivery by plurality, Australia and New Zealand, 1996 to 2005 | 46 |

Supplementary tables

The supplementary tables are available on the Internet at <www.npsu.unsw.edu.au>.

List of figures

| | |
|---|----|
| Figure 1: Proportion of ART treatment cycles by treatment type and procedure, Australia and New Zealand, 2005..... | 5 |
| Figure 2: Proportion of fresh embryo transfer cycles by number of embryos transferred per cycle and women's age group, Australia and New Zealand, 2005..... | 7 |
| Figure 3: Proportion of thawed embryo transfer cycles by number of embryos transferred per cycle and women's age group, Australia and New Zealand, 2005..... | 8 |
| Figure 4: Progression of autologous fresh cycles, Australia and New Zealand, 2005..... | 13 |
| Figure 5: Proportion of autologous fresh cycles that resulted in a live delivery by women's age group, Australia and New Zealand, 2005..... | 14 |
| Figure 6: Proportion of autologous fresh cycles with embryo transfer that resulted in a live delivery by number of embryos transferred and stage of embryo development, fertility centres, Australia and New Zealand, 2005..... | 17 |
| Figure 7: Progression of autologous thaw cycles, Australia and New Zealand, 2005..... | 18 |
| Figure 8: Proportion of autologous thaw cycles that resulted in a live delivery by women's age group, Australia and New Zealand, 2005..... | 19 |
| Figure 9: Proportion of autologous thaw cycles with embryo transfer that resulted in a live delivery by number of embryos transferred and stage of embryo development, Australia and New Zealand, 2005..... | 21 |
| Figure 10: Progression of oocyte donation cycles, Australia and New Zealand, 2005..... | 22 |
| Figure 11: Progression of recipient cycles following embryo transfers, Australia and New Zealand, 2005..... | 24 |
| Figure 12: Number of babies born to women who had embryo transfer cycles by gestational age, Australia and New Zealand, 2005..... | 32 |
| Figure 13: Number of liveborn babies to women who had embryo transfer cycles by birthweight and plurality, Australia and New Zealand, 2005..... | 34 |
| Figure 14: Proportion of embryo transfer cycles by number of embryos transferred, Australia and New Zealand, 2002 to 2005..... | 44 |
| Figure 15: Number of ART treatment cycles that resulted in a clinical pregnancy and a live delivery, Australia and New Zealand, 1996 to 2005..... | 45 |